GlassScriptPhysician profile
Rebecca Mobley
NPI 1790072783
$3,707.78
in general payments reported to CMS, 2019-2025
43 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $1,402 · 2023: $1,407 · 2024: $13.86 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.77 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $340.38 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $323.34 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $231.19 | 2021-2024 | Ingrezza, Ongentys |
| Ucb, INC. | $210.47 | 2021-2023 | Briviact |
| Lilly USA, LLC | $205.31 | 2021-2023 | Amyvid, Emgality, Reyvow |
| Biogen, INC. | $190.15 | 2021-2023 | Vumerity, Tysabri, Plegridy |
| Amgen INC. | $188.55 | 2021-2023 | Aimovig |
| Kyowa Kirin, INC. | $163.11 | 2021-2023 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $129.57 | 2021-2023 | Austedo, Austedo Xr |
| Sk Life Science, INC. | $121.64 | 2021-2023 | |
| Eisai INC. | $114.63 | 2021-2023 | |
| Upsher-Smith Laboratories LLC | $109.03 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $102.51 | 2021-2022 | |
| Janssen Biotech, INC. | $99.00 | 2025 | Rybrevant |
| Argenx US, INC. | $96.22 | 2022-2023 | Vyvgart |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.